Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

DISEASE CHARACTERISTICS: * Histologically proven hematologic malignancy of 1 of the following types: * Chronic myelogenous leukemia (CML) in chronic, accelerated, or blast\* phase * Acute leukemia with high-risk features at diagnosis such as: * Philadelphia chromosome-positive acute lymphocytic leukemia\*\* * Acute myeloid leukemia with high-risk cytogenetics such as inv (3), t(3;3) del(5q), -5, del(7q), -7, +8, +11, abnormal 12p, del(20q), -20, or complex abnormalities\*\* * Acute leukemia with failure after one course of induction chemotherapy * Acute leukemia in first relapse\* or second remission * High-risk lymphoblastic lymphoma in first remission * Non-Hodgkin's lymphoma, Hodgkin's disease, or other malignant lymphoproliferative disease after first remission, if an autologous transplantation is not indicated * Myelodysplastic or myeloproliferative syndromes ineligible for Protocol FHCRC-179 NOTE: \* For patients with acute leukemia in relapse or CML in blast crisis, the search for an unrelated donor begins only if: High probability that the patient's medical condition will remain stable for the 3 to 6-month period needed to find a donorAn attempt at remission induction has been undertaken Referring physician and patient accept possibility that search for donor will be canceled if patient's condition worsens NOTE: \*\* For newly diagnosed patients with high-risk acute leukemia, early referral is encouraged so that an unrelated donor search may begin immediately * Availability of an unrelated donor with: * 1 HLA-A or B non-cross-reactive group (non-CREG) mismatch (except in CML in chronic phase or myelodysplastic syndrome) OR * 1 HLA-A or B CREG mismatch OR * An HLA-A, B, and C match with an HLA-DRB1 or DQB1 mismatch (no double mismatch) if 1 of the above 2 donor types unavailable * No more than 1 HLA-A, B, and C mismatch * No availability of an HLA-identical sibling or haploidentical relative incompatible for 0 or 1 HLA-A or B locus of the nonshared haplotypes * For patients with diagnosis other than CML in chronic phase, 1 HLA-DR locus-incompatible related donor has priority over an HLA compatible or class IA or B CREG locus antigen-incompatible unrelated donor * No severe aplastic anemia * No leukoencephalopathy PATIENT CHARACTERISTICS: Age: * Under 51 * Eligible for transplantation until age 52 if the donor is identified prior to patient's 51st birthday Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics Hepatic: * No severe hepatic disease, including acute hepatitis Renal: * Creatinine less than 2 times normal Cardiovascular: * No cardiac insufficiency requiring treatment * No symptomatic coronary artery disease Pulmonary: * No severe hypoxemia (i.e., PO2 less than 70 mm Hg) with decreased DLCO (i.e., DLCO less than 70% predicted) OR * No mild hypoxemia (i.e., PO2 less than 80 mm Hg) with severely decreased DLCO (i.e., DLCO less than 60% predicted) * No pulmonary fibrosis Other: * No other nonmalignant disease that would severely limit life expectancy * HIV negative * No contraindication to total body irradiation (TBI) * Patients excluded from this study because of contraindication to TBI may be treated on protocol FHCRC-739 PRIOR CONCURRENT THERAPY: Biologic therapy: * See Disease Characteristics Chemotherapy: * See Disease Characteristics Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy greater than 3,000 cGy to whole brain * At least 6 months since prior involved-field radiotherapy greater than 1,500 cGy to chest or abdomen Surgery: * Not specified